PTH and chronic kidney disease: Despite these promising findings, the use of PTH analogs in CKD stages G4–G5D should be limited to carefully selected cases, particularly those with high fracture risk and low bone turnover (Figure 2), and requires close monitoring of calcium, phosphate, and PTH levels, since isolated cases of calciphylaxis have been reported in subjects treated with PTH analogs [66,67].